The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Zoetis (ZTS) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Zoetis is a member of the Medical sector. This group includes 840 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ZTS's full-year earnings has moved 1.24% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ZTS has returned 17.98% so far this year. Meanwhile, the Medical sector has returned an average of -3.45% on a year-to-date basis. This shows that Zoetis is outperforming its peers so far this year.
Looking more specifically, ZTS belongs to the Medical - Drugs industry, which includes 180 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, stocks in this group have lost 14.48% this year, meaning that ZTS is performing better in terms of year-to-date returns.
ZTS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zoetis Inc. (NYSE:ZTS): Free Stock Analysis Report
Original post